Stephen F Vatner, 8416 E 27Th St, Barnegat Light, NJ 08006

7009038, Mar 7, 2006

May 2, 2003

10/429223

Christophe Depre - New York NY, US
Stephen F. Vatner - New York NY, US

Univ. of Medicine & Dentistry of N.J. - New Brunswick NJ

C07K 1/00
C07K 14/00
C07K 17/00

530350, 514 12

The present invention provides novel nucleic acid and protein sequences for methods and compositions for treating, screening, and diagnosing cardiovascular disease and methods for using these genes and gene products for prevention of cardiac cell death and prevention of cardiac tissue damage resulting from ischemic events in cardiac tissue, as well as other tissue that is subject to damage resulting from an ischemic event. The genes, gene products and agents of the invention are also useful for treating other related clinical or coronary events such as angina, myocardial infarct (MI), and stroke, for monitoring the effectiveness of their treatment, and for drug development. The genes, gene products and agents of the present invention are also provided as pharmaceutical compositions for treatment of cardiovascular disease, ischemic heart disease, myocardial infarct and related conditions. Kits are also provided for the diagnosis, treatment and prognosis of cardiac diseases and related conditions.

7160859, Jan 9, 2007

Oct 10, 2003

10/683576

Stephen F. Vatner - New York NY, US
Junichi Sadoshima - Berkeley Heights NJ, US

University of Medicine & Dentistry of New Jersey - New Brunswick NJ

A61K 38/00
C07K 1/00
G01N 33/53

514 12, 530350, 435 71

The present invention relates to methods and agents for treatment, amelioration and prevention of cardiac disease, including cardiac myopathy, chronic heart failure and for management and reduction of cardiac myocyte death which may occur in response to ischemia/reperfusion or following myocardial infarction or other injury to the heart. The invention relates to methods for screening cardiotherapeutic compounds, including compounds which modulate cardiac myocyte apoptosis, particularly targeting Mst1 and the Mst1 pathway. The present invention further encompasses compounds identified by such screening methods and compositions comprising these compounds. The invention also provides methods for treatment, amelioration and prevention of cardiac disease comprising administering compounds or agents which modulate, particularly inhibit, Mst1 or the Mst1 kinase pathway, including administering a nucleic acid encoding an altered form of Mst1, particularly a dominant negative Mst1, which acts as an antagonist of Mst1.

7803908, Sep 28, 2010

Mar 1, 2006

11/365484

Christophe Depre - New York NY, US
Stephen F. Vatner - New York NY, US

University of Medicine and Dentistry of New Jersey - New Brunswick NJ

C07K 1/00

530350, 530300, 536 231

The present invention provides novel nucleic acid and protein sequences for methods and compositions for treating, screening, and diagnosing cardiovascular disease and methods for using these genes and gene products for prevention of cardiac cell death and prevention of cardiac tissue damage resulting from ischemic events in cardiac tissue, as well as other tissue that is subject to damage resulting from an ischemic event. The genes, gene products and agents of the invention are also useful for treating other related clinical or coronary events such as angina, myocardial infarct (MI), and stroke, for monitoring the effectiveness of their treatment, and for drug development. The genes, gene products and agents of the present invention are also provided as pharmaceutical compositions for treatment of cardiovascular disease, ischemic heart disease, myocardial infarct and related conditions. Kits are also provided for the diagnosis, treatment and prognosis of cardiac diseases and related conditions.

7846683, Dec 7, 2010

Sep 23, 2005

11/575887

Stephen F. Vatner - New York NY, US
Christopher Depre - New York NY, US

University of Medicine and Dentistry of New Jersey - New Brunswick NJ

C12Q 1/48

435 15

The present invention relates to a method for identifying an agent. for modulating cell growth or survival. The method involves the identification of an agent which modulates the net ratio of nuclear-localized versus cytosolic-localized H11 kinase or mutant H11 kinase in a cell. A method for diagnosing a cancer associated with H11 kinase or Akt activation in a subject is also provided.

8263401, Sep 11, 2012

May 26, 2005

11/597065

Stephen F. Vatner - Barnegat Light NJ, US
Dorothy E. Vatner - Barnegat Light NJ, US
Junichi Sadoshima - Berkeley Heights NJ, US
Jayashree Pain - Livingston NJ, US

University of Medicine and Dentistry of New Jersey - Somerset NJ

C12N 5/20
C07K 16/40
C07H 7/00

435326, 435338, 53038826

The invention relates to compositions and methods for diagnosing and treating cardiac conditions and neurodegenerative diseases using antibodies which specifically recognize and bind to the adenylyl cyclase 5 isoform in the heart and brain. These antibodies demonstrate high specificity to the AC5 isoform and do not cross react to any other AC5 isoform. The invention further relates to methods of delivery of drugs to the site of injured tissue using the antibodies of the present invention.

8440640, May 14, 2013

Nov 18, 2009

13/129586

Stephen F. Vatner - New York NY, US

University of Medicine and Dentistry of New Jersey - Somerset NJ

A01N 43/04
A61K 31/70

514 46, 514 43, 514 45, 514 47, 514 48

The invention provides methods for, and compositions effective for, treating obesity, inhibiting weight gain, treating diabetes mellitus, inhibiting atherosclerosis and treating related disorders and conditions comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to a patient. The compound capable of inhibiting AC5 may be administered singly or in combination with another agent. In some embodiments, the AC5 inhibiting compound is 9-β-D-arabinofuranosyladenine (AraAde). The compounds may be administered in an amount of about 1 to about 200 mg/kg/day, about 1 to about 100 mg/kg/day, about 10 to about 80 mg/kg/day, about 12 to about 40 mg/kg/day or about 15 to about 25 mg/kg/day. In some embodiments, the compound is administered orally.

2006025, Nov 9, 2006

May 2, 2003

10/429214

Stephen Vatner - New York NY, US

A61K 31/52

514263200, 514263230

The invention concerns pharmaceutical compositions that contain a compound or compounds that can effectively regulate the activity of Type 5 Adenylyl Cyclase and methods for treatment of neurological diseases and disorders, as well as motor function loss therefrom, as well as treatment for cardiac conditions and diseases including conditions characterized by abnormal heart rate.

2007027, Nov 29, 2007

Nov 28, 2006

11/605197

Stephen Vatner - New York NY, US
Junichi Sadoshima - Berkeley Heights NJ, US

C12Q 1/02
A01K 67/027
A61K 31/00
A61K 31/7034
A61K 31/7088
A61K 33/00
A61P 9/00
C12N 5/00

424718000, 514026000, 514044000, 514789000, 800009000

The present invention relates to methods and agents for treatment, amelioration and prevention of cardiac disease, including cardiac myopathy, chronic heart failure and for management and reduction of cardiac myocyte death which may occur in response to ischemia/reperfusion or following myocardial infarction or other injury to the heart. The invention relates to methods for screening cardiotherapeutic compounds, including compounds which modulate cardiac myocyte apoptosis, particularly targeting Mst1 and the Mst1 pathway. The present invention further encompasses compounds identified by such screening methods and compositions comprising these compounds. The invention also provides methods for treatment, amelioration and prevention of cardiac disease comprising administering compounds or agents which modulate, particularly inhibit, Mst1 or the Mst1 kinase pathway, including administering a nucleic acid encoding an altered form of Mst1, particularly a dominant negative Mst1, which acts as an antagonist of Mst1.